MP Advisors

MP Advisors is an independent company offering research and paramount knowledge within a healthcare industry. At present great many global pharmaceutical companies, especially in U.S., Europe, Russia, India and Japan are among MP Advisors’s clients. When founded, 1996, the agency is ensuring investment solutions and assessing investment opportunities with a penetrating eye on risks and benefits from funding pharma manufacturing.

MP Advisors unparalleled service includes:
  • Financial Analysis;
  • Competitive landscaping;
  • Macro Analysis;
  • Technology Transfer;
  • Mergers & Acquisitions;
  • Strategic planning;
  • Forecast.
Customized reports are in the focus area of skillful and competent experts who explore, analyze and interpret data, select tools and approaches on how efficiently reach ultimate market decisions and reach maximum understanding of current biotech and therapeutic issues.

More than 200 medical companies’ profiles are in its database. MP Advisors publishes insightful reports fortified by proficient views of key specialists. Moreover, it produces ad hoc reports on Japan and Indian generic drug, Para IV, oncology, obesity and other therapy reviews.


Research Reports By MP Advisors

Found 450 publications
Global Pharmaceutical and Biotechnology Outlook 2014: Rising Stars US$ 2,500.00 US$ 2,125.00 Jan, 2014 113 pages
Global Pharmaceutical and Biotechnology Outlook 2014 - India Pharma US$ 2,500.00 US$ 2,125.00 Jan, 2014 66 pages
Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma US$ 2,500.00 US$ 2,125.00 Jan, 2014 141 pages
TAKEDA , Challenges Ahead for its New European Presiden US$ 500.00 US$ 425.00 Jan, 2014 24 pages
Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU US$ 2,500.00 US$ 2,125.00 Jan, 2014 113 pages
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech US$ 2,500.00 US$ 2,125.00 Jan, 2014 145 pages
Enanta- It is just the beginning of good news US$ 90.00 US$ 76.50 Nov, 2013 2 pages
Therapy Class Overview : Hepatitis C Virus Infection US$ 1,000.00 US$ 850.00 Oct, 2013 33 pages
Therapy Class Overview: Rituximab biosimilar US$ 2,000.00 US$ 1,700.00 Oct, 2013 45 pages
Incyte- INCB39110 – Another JAK-Fruit in INCY’s Basket US$ 140.00 US$ 119.00 Oct, 2013 5 pages
ABLYNX - Nanobodies - Turnarond on the Horizon! US$ 140.00 US$ 119.00 Oct, 2013 7 pages
MEDIVIR - Simeprevir- Good with and without IFN Combinations! US$ 140.00 US$ 119.00 Oct, 2013 3 pages
1 2 3 4 5 ... 9
Skip to top

Analytics, News & Press-Releases by MP Advisors